Share Article

Funds from the animal health company will be used to support VHF’s mission to bring awareness and hope to the veterinary community
DULUTH, Ga., Oct. 10, 2022 /PRNewswire/ — Boehringer Ingelheim Animal Health USA Inc. is honored to support the Veterinary Hope Foundation (VHF) with a $225,000 sponsorship. The VHF is a not-for-profit focused on providing education and connection programs to benefit the health of the veterinary community. The sponsorship will support VHF’s mission, including funding small groups to provide veterinary professionals with resources, information and community support to better handle the stressors and mental health issues unique to the profession. With this contribution, Boehringer Ingelheim becomes a founding sponsor of the Veterinary Hope Foundation.
The Veterinary Hope Foundation’s support groups provide veterinary professionals–who are three times more likely1 than the general population to die by suicide–with early intervention efforts and allow them to connect in a safe, confidential and caring space. These groups, led by a licensed mental health professional, focus on topics meaningful to practicing veterinarians and their teams such as communicating with troubled clients, balancing family and work, handling grief and cultivating emotional resilience.
“We are tremendously thankful for the partnership of Boehringer Ingelheim and the support of our mission to provide resources to those in the animal care community,” said Dr. Blair McConnel, veterinarian and president of the board of the Veterinary Hope Foundation. “I look forward to working with the passionate team at Boehringer Ingelheim. I hope that this sponsorship will spur other pet care and animal health companies into necessary action.”
In addition to the sponsorship, Boehringer Ingelheim will advocate and share VHF’s mission as their teams visit veterinary clinics across the country. The teams will leave behind information about resources available to help the clinic spread awareness of the VHF’s cause and how veterinarians and their teams can get involved. Boehringer Ingelheim continued to elevate VHF’s mission during the 2022 Veterinary Meeting & Expo (VMX), the world’s largest veterinary conference, held Jan. 15-19. Boehringer Ingelheim helped VHF spread hope to over 12,000 conference attendees by giving booth space to VHF’s informational pamphlets.
“We are proud to be a founding sponsor of the Veterinary Hope Foundation and partner to help bring to life their mission of raising awareness and providing resources to those in the animal care community who may be facing struggles we don’t see,” said Shawn Hooker, Head of Pet Business at Boehringer Ingelheim Animal Health USA Inc. “Each day, veterinarians are there for us. This is one way we are choosing to illustrate our dedication to supporting veterinarians and their teams.”
Results from the first support groups are overwhelmingly positive. One veterinarian noted, “It’s exactly what I didn’t know I needed, but [the group] provided me with more insight than months of 1:1 therapy.” All support group participants who were polled said they would strongly recommend this program to other veterinarians.
You can learn more about the foundation, its mission, and how you or your organization can join the cause at
About the Veterinary Hope Foundation
Founded in May 2021, the Veterinary Hope Foundation (VHF) is a not-for-profit focused on early intervention, education and connection programs tailored for the animal care community. Built on the belief that there’s hope for veterinarians in crisis, VHF provides veterinarians with the tools and support they need to navigate the common stressors unique to their profession. With veterinarians about three times more likely1 than the general population to die by suicide, VHF aims to generate broad awareness of the issue and generate lasting change through its public awareness campaign. Governed by a board of directors and advisory panel composed of mental health experts, practicing veterinarians and animal lovers, VHF is uniquely positioned to impact the future of the veterinarian profession. To learn more about VHF, please visit and follow us on FacebookTwitter, LinkedIn and Instagram.
About Boehringer Ingelheim Animal Health USA 
Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, producers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock.
As a global leader in the animal health industry and as part of the family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both.
Boehringer Ingelheim Animal Health has deep roots in the U.S. From a start in St. Joseph, Missouri, more than 100 years ago, it has grown to encompass seven sites. Boehringer Ingelheim Animal Health’s portfolio contains widely used and well-respected vaccines, parasite-control products and therapeutics for pets, horses and livestock including NexGard® (afoxolaner) Chewables, HEARTGARD® Plus (ivermectin/pyrantel) Chewables, Pyramid® 5 + Presponse® SQ, VAXXITEK®, CircoFLEX®, and Prascend® (pergolide tablets).
Learn more about Boehringer Ingelheim Animal Health USA at
NexGard® is a registered trademark of the Boehringer Ingelheim Group.
HEARTGARD®, PYRAMID®, VAXXITEK®, and PRESPONSE® are registered trademarks of Boehringer Ingelheim Animal Health USA Inc. INGELVAC CIRCOFLEX® and PRASCEND® are registered trademarks of Boehringer Ingelheim Vetmedica GmbH. All other trademarks are the property of their respective owner. ©2022 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0393-2022-V2.
1. Tomasi SE, Fechter-Leggett ED, Edwards NT, Reddish AD, Crosby AE, Nett RJ. Suicide among veterinarians in the United States from 1979 through 2015. J Am Vet Med Assoc. 2019;254(1):104-112.
Media Contacts:
Chrissy Jones
Boehringer Ingelheim Animal Health
U.S. Communications
(516) 527-5456
[email protected]
Blair McConnel
Veterinary Hope Foundation 
[email protected]
View original content to download multimedia:
SOURCE Boehringer Ingelheim
Merck & Co Inc (NYSE: MRK) announced topline results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept, an investigational activin receptor type IIA-Fc fusion protein as an add-on to stable background therapy for pulmonary arterial hypertension (PAH). The drug is designed to tone down inflammation in PAH patients, a rare type of high blood pressure that affects the arteries in the lungs and the right side of the heart. Merck added sotatercept, the lead drug
Amylyx’s $158,000 price tag for a recently approved ALS drug is the latest example of how out of whack drug prices have become in the U.S.
Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.
The company hopes the drug, sotatercept, will help make up for revenue it will lose when the patent on a blockbuster cancer therapeutic expires at the end of this decade.
Although Biogen and Eisai’s lecanemab cleared plaque from patients’ brains, researchers say the benefits may be limited.
“We don’t even know how long that has been happening, or if anybody else is going through it,” family of the injured grandpa said.
Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), announced data from an ongoing analysis of a Phase 2a trial of guselkumab and golimumab combo therapy for ulcerative colitis. The results showed that 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission rate at week 38 of 47.9%, a higher rate than induction and maintenance treatment with either guselkumab alone (31%) or g
Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.
A new study from Europe has found that the benefits of regular colonoscopies in helping reduce the risk of colorectal cancer and death may have been overestimated due to gaps in evidence. The Nordic-European Initiative on Colorectal Cancer (NordICC) conducted a trial involving nearly 85,000 people between ages 55 and 64. The study sample included…
A new poll shows that only 49% of adults in the U.S. plan to get a flu vaccine. CBS News medical contributor Dr. Celine Gounder joins "CBS Mornings" to explain who is most at risk for getting the flu and why now is the time to get the flu vaccine.
By Mark Gilman — Benzinga
Chief White House medical adviser Anthony Fauci on Monday warned that the U.S. should not ease up on its COVID-19 response as variants continue to circulate and as the country heads into the winter flu season. “We have a ways to go, particularly as we enter the winter, which will be complicated by the influenza season. So…
Here’s how Arians established a game plan to manage his heart health, and why he’s encouraging others to do the same.
Brian Kelly updated the status of the two offensive linemen after Saturday's loss to Tennessee.
A new study suggests an association between whole grains and heart health..
Many families across the U.S. lack access to supplies essential to their baby's well-being, including clothing, food, and diapers.
Findings may lead to better understanding of psychiatric conditions like PTSD
If you're 65 or older, then Medicare is there to help you get the healthcare coverage you need. For hospital and inpatient care, Medicare Part A is the choice that tens of millions of people turn to. But for covering routine doctor visits and other outpatient care, Medicare Part B is the traditional option for many participants in the program. has an extensive editorial partnership with Cleveland Clinic, consistently named as one of the nation's best hospitals in U.S. News & World Report's annual "America's Best Hospitals" survey. Click here to learn more about our health reporting policies. It’s no surprise that people’s …
Some experts worry that lower booster rates will help the virus mutate this fall and winter.


You might also like

Surviving 2nd wave of corona

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort